Year: 2015
Type: review
Abstract: Understanding the molecular landscape of cancer has facilitated the development of diagnostic, prognostic, and predictive biomarkers for clinical oncology. Developments in next-generation DNA sequencing technologies have increased the speed and reduced the cost of sequencing the nucleic acids of cancer cells. This has unlocked opportunities to characterize the genomic and transcriptomic landscapes of cancer for basic science research through projects like The Cancer Genome Atlas. The cancer genome includes DNA-based alterations, such as point mutations or gene duplications. The cancer transcriptome involves RNA-based alterations, including changes in messenger RNAs. Together, the genome and transcriptome can provide a comprehensive view of an individual patient's cancer that is beginning to impact real-time clinical decision-making. The authors discuss several opportunities for translating this basic science knowledge into clinical practice, including a molecular classification of cancer, heritable risk of cancer, eligibility for targeted therapies, and the development of innovative, genomic-based clinical trials. In this review, key applications and new directions are outlined for translating the cancer genome and transcriptome into patient care in the clinic.
DOI: 10.3322/caac.21329
Authors: Sameek Roychowdhury, Arul M. Chinnaiyan
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,330
Awards: Exploring Precision Cancer Medicine for Sarcoma and Rare Cancers, G2551538412, G397898405, SPORE in Prostate Cancer, Michigan Prostate SPORE 2025-2030, Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas Southwestern
OpenAlex ID: W1936243389
